EUVIMEDEUVIMED entdecken
Multizentrische Studie

Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg‐Negative Chronic Hepatitis B

Cheng-Hao Tseng iD, Teng-Yu Lee iD, Chi-Yi Chen, Chung-Feng Huang iD, Po-Yueh Chen, Tyng-Yuan Jang iD, Tzeng-Huey Yang, Chia-Ching Wu, Yao-Chun Hsu iD

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.16923 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Cheng-Hao Tseng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, E-DA Cancer Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Tenofovir, Guanine, Hepatitis B e Antigens. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: E-Da Hospital, E-Da Cancer Hospital, Liver Disease Prevention and Treatment Research Foundation of Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim The relapse pattern following the discontinuation of tenofovir alafenamide (TAF) in patients with chronic hepatitis B (CHB) remains unclear. This study aimed to compare the 2‐year incidences of virological and clinical relapses among patients who discontinued TAF versus those who discontinued tenofovir disoproxil fumarate (TDF) or entecavir (ETV).

Methods

This multicenter retrospective study enrolled noncirrhotic hepatitis B e antigen (HBeAg)‐negative CHB patients who discontinued TAF, TDF, or ETV with undetectable HBV DNA at treatment cessation. For patients who switched from ETV or TDF to TAF, a minimum TAF exposure duration of 12 months was required for inclusion in the off‐TAF group. Inverse probability of treatment weighting was employed to adjust for baseline differences.

Results

A total of 162 patients (off‐TAF: 37, off‐TDF: 87, off‐ETV: 38) were included in the primary analysis. The 2‐year cumulative incidence of virological relapse was significantly higher in the off‐TAF group (85.0%) compared to the off‐TDF group (69.5%, p = 0.024) and the off‐ETV group (51.5%, p = 0.010). Similarly, the 2‐year cumulative incidence of clinical relapse was significantly higher in the off‐TAF group (62.4%) compared to the off‐TDF group (39.0%, p = 0.026) and the off‐ETV group (22.5%, p = 0.024). Consistent results were observed in patients meeting the 2012 APASL stopping criteria.

Conclusions

HBeAg‐negative patients who discontinue TAF face a higher risk of both virological and clinical relapses compared to those discontinuing TDF or ETV. These findings underscore the need for more intense monitoring in CHB patients after TAF cessation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicTenofovirGuanineHepatitis B e AntigensAntiviral AgentsAdenineWithholding TreatmentHumansMaleFemaleRetrospective StudiesRecurrenceMiddle AgedAdultIncidenceAlanineDNA, ViralHepatitis B virusTime Factors

Stichwörter der Autor:innen

antiviralscomparative studyhepatitis B virustreatment cessation

Substanzen

TenofovirentecavirGuanineHepatitis B e AntigensAntiviral Agentstenofovir alafenamideAdenineAlanineDNA, Viral

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, E-DA Cancer Hospital, Kaohsiung, Taiwan.
  • Division of Gastroenterology and Hepatology, E-DA Hospital, Kaohsiung, Taiwan.
  • School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Division of Gastroenterology and Hepatology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan.

ORCID-Profile: Cheng-Hao Tseng, Teng-Yu Lee, Chung-Feng Huang, Tyng-Yuan Jang, Yao-Chun Hsu

Förderung

  • E-Da Hospital
  • E-Da Cancer Hospital
  • Liver Disease Prevention and Treatment Research Foundation of Taiwan

Zitieren

APA

Tseng, C. H., Lee, T. Y., Chen, C. Y., Huang, C. F., Chen, P. Y., Jang, T. Y., Yang, T. H., Wu, C. C., & Hsu, Y. C. (2025). Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg‐Negative Chronic Hepatitis B. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16923

Vancouver

Tseng CH, Lee TY, Chen CY, Huang CF, Chen PY, Jang TY, et al. Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg‐Negative Chronic Hepatitis B. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.16923

BibTeX
@article{Tseng2025,
  author = {Tseng, Cheng-Hao and Lee, Teng-Yu and Chen, Chi-Yi and Huang, Chung-Feng and Chen, Po-Yueh and Jang, Tyng-Yuan and Yang, Tzeng-Huey and Wu, Chia-Ching and Hsu, Yao-Chun},
  title = {Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg‐Negative Chronic Hepatitis B},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.16923}
}
Kostenlos starten →